Azita Haddadi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7180129/publications.pdf

Version: 2024-02-01

29 papers	1,704 citations	430754 18 h-index	477173 29 g-index
29 all docs	29 docs citations	29 times ranked	3211 citing authors

#	Article	IF	Citations
1	Establishment of the tandem mass spectrometric fingerprints of taxaneâ€based anticancer compounds. Rapid Communications in Mass Spectrometry, 2021, 35, e9107.	0.7	8
2	Vaccine Formulation for Infectious Diseases and Adjuvant Mechanisms of Action. Vaccines, 2021, 9, 667.	2.1	1
3	Combination of Innate Immune Modulators as Vaccine Adjuvants in Mice. Vaccines, 2020, 8, 569.	2.1	6
4	Prospects for RNAi Therapy of COVID-19. Frontiers in Bioengineering and Biotechnology, 2020, 8, 916.	2.0	69
5	A robust systematic design: Optimization and preparation of polymeric nanoparticles of PLGA for docetaxel intravenous delivery. Materials Science and Engineering C, 2019, 104, 109950.	3.8	41
6	Potentiating Antigen Specific Immune Response by Targeted Delivery of the PLGA-Based Model Cancer Vaccine. Molecular Pharmaceutics, 2019, 16, 498-509.	2.3	10
7	Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine. International Journal of Nanomedicine, 2018, Volume 13, 367-386.	3.3	26
8	Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a. Degenerative Neurological and Neuromuscular Disease, 2017, Volume 7, 47-60.	0.7	6
9	Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. International Journal of Nanomedicine, 2017, Volume 12, 935-947.	3.3	205
10	Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer. Journal of Drug Delivery, 2017, 2017, 1-24.	2.5	93
11	Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery. Pharmaceutical Nanotechnology, 2017, 5, 3-23.	0.6	37
12	Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer. Current Cancer Drug Targets, 2015, 15, 71-86.	0.8	30
13	Investigation and optimization of formulation parameters on preparation of targeted anti-CD205 tailored PLGA nanoparticles. International Journal of Nanomedicine, 2015, 10, 7371.	3.3	16
14	Optimization of nanoparticles for cardiovascular tissue engineering. Nanotechnology, 2015, 26, 235301.	1.3	18
15	Application of a Rapid ESI-MS/MS Method for Quantitative Analysis of Docetaxel in Polymeric Matrices of PLGA and PLGA-PEG Nanoparticles through Direct Injection to Mass Spectrometer. American Journal of Analytical Chemistry, 2015, 06, 164-175.	0.3	8
16	Presence of monoterpene synthase in four Labiatae species and Solid-Phase Microextraction- Gas chromatography-Mass Spectroscopy analysis of their aroma profiles. Pharmacognosy Research (discontinued), 2014, 6, 138.	0.3	3
17	Immunoadjuvant activity of the nanoparticlesâ€™ surface modified with mannan. Nanotechnology, 2014, 25, 355101.	1.3	26
18	Biogenic trypanocidal sesquiterpenes: lead compounds to design future trypanocidal drugs - a mini review. DARU, Journal of Pharmaceutical Sciences, 2013, 21, 35.	0.9	12

#	Article	IF	Citations
19	Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052. Photochemistry and Photobiology, 2012, 88, 188-193.	1.3	14
20	STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo. Translational Oncology, 2011, 4, 178-188.	1.7	37
21	Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. Journal of Drug Targeting, 2011, 19, 281-292.	2.1	68
22	Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Advanced Drug Delivery Reviews, 2011, 63, 943-955.	6.6	257
23	Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles. Pharmaceutical Research, 2011, 28, 2288-2301.	1.7	97
24	STAT3 Silencing in Dendritic Cells by siRNA Polyplexes Encapsulated in PLGA Nanoparticles for the Modulation of Anticancer Immune Response. Molecular Pharmaceutics, 2010, 7, 1643-1654.	2.3	86
25	Formulation and Delivery of siRNA by Oleic Acid and Stearic Acid Modified Polyethylenimine. Molecular Pharmaceutics, 2009, 6, 121-133.	2.3	132
26	Resveratrol analog trans 3,4,5,4â€²-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemotherapy and Pharmacology, 2008, 63, 27-35.	1.1	68
27	Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. Journal of Biomedical Materials Research - Part A, 2008, 84A, 885-898.	2.1	72
28	Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine, 2008, 26, 5046-5057.	1.7	227
29	Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (d,l-lactic-co-glycolic) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	31